Ensysce Biosciences Investor Relations Material

Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company focused on developing innovative drug delivery technologies aimed at improving safety in pain management. The company is known for its development of two proprietary platforms: the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). These platforms are designed to reduce the risks associated with prescription opioid misuse, abuse, and overdose by enhancing the safety of oral drug delivery. Ensysce's product pipeline includes prodrug technologies that aim to provide effective pain relief while mitigating the potential for abuse and overdose. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ under the ticker symbol ENSC.